prednisolone has been researched along with Gastrointestinal Stromal Tumors in 5 studies
Prednisolone: A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.
prednisolone : A glucocorticoid that is prednisone in which the oxo group at position 11 has been reduced to the corresponding beta-hydroxy group. It is a drug metabolite of prednisone.
Gastrointestinal Stromal Tumors: All tumors in the GASTROINTESTINAL TRACT arising from mesenchymal cells (MESODERM) except those of smooth muscle cells (LEIOMYOMA) or Schwann cells (SCHWANNOMA).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Imatinib mesylate is a drug that has been approved for treatment of chronic myeloid leukemia, Philadelphia-positive acute lymphoblastic leukemia, and advanced gastrointestinal stromal tumors." | 7.76 | Imatinib mesylate-induced acute liver failure in a patient with gastrointestinal stromal tumors. ( Akyurek, N; Benekli, M; Buyukberber, S; Coskun, U; Demirci, U; Karakan, T; Tonyali, O; Yildiz, R, 2010) |
| "Imatinib mesylate is a drug that has been approved for treatment of chronic myeloid leukemia, Philadelphia-positive acute lymphoblastic leukemia, and advanced gastrointestinal stromal tumors." | 3.76 | Imatinib mesylate-induced acute liver failure in a patient with gastrointestinal stromal tumors. ( Akyurek, N; Benekli, M; Buyukberber, S; Coskun, U; Demirci, U; Karakan, T; Tonyali, O; Yildiz, R, 2010) |
| "Perifosine is a novel alkylphospholipid with antiproliferative properties attributed to protein kinase B inhibition." | 2.73 | Ulcerative keratitis in gastrointestinal stromal tumor patients treated with perifosine. ( Araujo, DM; Esmaeli, B; Espandar, L; Hatef, E; Kim, SK; Shome, D; Song, CD; Trent, J, 2008) |
| " The reintroduced imatinib dosage was stepped up every week starting from 10 mg/d and increasing to 25, 50, 75, 100, 150, 200, and 300 mg/d until the target dose of 400 mg/d was achieved." | 1.43 | Slow desensitization of imatinib-induced nonimmediate reactions and dynamic changes of drug-specific CD4 ( Buranapraditkun, S; Klaewsongkram, J; Mongkolpathumrat, P; Sodsai, P; Thantiworasit, P, 2016) |
| " Treatment continued without obvious side effects, and PDL dosage was tapered to 10 mg/day." | 1.36 | [Complete response achieved in a case of gastric gastrointestinal stromal tumor by administration of imatinib mesilate with concurrent relatively high-dose steroid therapy to control side effects]. ( Kishimoto, H; Nakamura, M; Otagiri, N; Sasahara, K; Tauchi, K; Tsukada, Y; Yoshifuku, S, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Klaewsongkram, J | 1 |
| Thantiworasit, P | 1 |
| Sodsai, P | 1 |
| Buranapraditkun, S | 1 |
| Mongkolpathumrat, P | 1 |
| Tonyali, O | 1 |
| Coskun, U | 1 |
| Yildiz, R | 1 |
| Karakan, T | 1 |
| Demirci, U | 1 |
| Akyurek, N | 1 |
| Benekli, M | 1 |
| Buyukberber, S | 1 |
| Tsukada, Y | 1 |
| Tauchi, K | 1 |
| Nakamura, M | 1 |
| Kishimoto, H | 1 |
| Yoshifuku, S | 1 |
| Otagiri, N | 1 |
| Sasahara, K | 1 |
| Bompas, E | 1 |
| Velay, B | 1 |
| Blay, JY | 1 |
| Shome, D | 1 |
| Trent, J | 1 |
| Espandar, L | 1 |
| Hatef, E | 1 |
| Araujo, DM | 1 |
| Song, CD | 1 |
| Kim, SK | 1 |
| Esmaeli, B | 1 |
1 trial available for prednisolone and Gastrointestinal Stromal Tumors
| Article | Year |
|---|---|
Ulcerative keratitis in gastrointestinal stromal tumor patients treated with perifosine.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Corne | 2008 |
4 other studies available for prednisolone and Gastrointestinal Stromal Tumors
| Article | Year |
|---|---|
Slow desensitization of imatinib-induced nonimmediate reactions and dynamic changes of drug-specific CD4
Topics: Adult; Aged; Antineoplastic Agents; CD4-Positive T-Lymphocytes; Desensitization, Immunologic; Drug H | 2016 |
Imatinib mesylate-induced acute liver failure in a patient with gastrointestinal stromal tumors.
Topics: Acute Disease; Anti-Inflammatory Agents; Antineoplastic Agents; Benzamides; Chemical and Drug Induce | 2010 |
[Complete response achieved in a case of gastric gastrointestinal stromal tumor by administration of imatinib mesilate with concurrent relatively high-dose steroid therapy to control side effects].
Topics: Benzamides; Drug Eruptions; Drug Therapy, Combination; Gastrointestinal Stromal Tumors; Humans; Imat | 2010 |
Combination treatment of rituximab and imatinib mesylate for simultaneous relapse of MALT lymphoma and a gastrointestinal stromal tumor.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Agent | 2004 |